AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board

/in

Seasoned executive with extensive board experience across US and European biotechnology companies Brings extensive operational, strategic and transactional expertise as AstronauTx advances its innovative pipeline targeting improvements in sleep architecture to treat neurodegenerative diseases   London, UK, 7 January 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other […]

Read more

Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation

/in

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers Phase 2 trial will assess the efficacy of AP31969 on atrial fibrillation burden and its safety profile using continuous cardiac rhythm monitoring Copenhagen, Denmark, 6 January 2026 – Acesion […]

Read more

LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease

/in

LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ Unique mechanism of action with potential to slow or stop the progression of HD Cambridge, UK, 6 January 2026 – LoQus23 Therapeutics Ltd (“LoQus23”), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause […]

Read more

numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON ® LDLp Test System

/in

AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysia numares Health appoints BioD Medica for local distribution MDA filing for additional CE-marked product is currently in progress   Regensburg, Germany, 16 December 2025 – numares Health (“numares”), the transformative metabolomics company pioneering multidimensional biomarker insights that deliver clinical pathways for optimal patient care, […]

Read more

Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering

/in

Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM  London, UK and Chicago, IL – 15 December 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, and Syenex, an open-science genetic medicines platform company, today announced a strategic collaboration […]

Read more
© Optimum Strategic Communications.